“…3,37 As seen in Argentina, we saw high prevalence of G3P [8] and G2P [4] genotypes. 3 Similar to Brazilian and Argentine populations, Bolivia experienced an increase in G2P [4] genotypes immediately before vaccine introduction, suggesting year-to-year variability toward this genotype. 5,6,37 The G1P [8]-derived vaccine is effective against genotypes heterotypic to the vaccine type, including the G2P [4] genotype that some have suggested is favored after vaccination.…”